|Day Low/High||647.54 / 664.90|
|52 Wk Low/High||492.13 / 747.42|
The EV maker looks ripe for a dip, while the pharmaceutical giant and chip producer could make for swing trades.
Plus, while market breadth stunk yesterday, it was on lower trading volume, which is an encouraging sign.
Seven investment experts participating in Moneyshow's Top Picks 2022 report share their ideas for healthy portfolio gains in 2022.
Here's how aggressive traders could play this biotech giant -- and our targets for the name.
Sector selection will remain paramount as pandemic effects continue to permeate.
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
The challenge for traders is determining how long the Omicron uncertainty will weigh on the markets.
Small-cap biotech names are seeing dramatic, widespread declines, creating a liquidation sale for investors.
Look for business travel to pick up in a big way in 2022 as the pandemic winds down, which is why American Airlines is a stock to consider.
Let's look at how we can go higher and what must go right before the advance has staying power.
The Real Money Post Industrial Average is now up 18.2% -- here's why it could still plow ahead of the Dow and S&P 500.
Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.
AbbVie has been a Sarge fave for a long time. Sarge has been rewarded for trusting this firm's management when they acquired Allergan as a means toward replacing expected reductions in cash flows moving forward as the firm's patents for winder dru...
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
We just got hit with a two-by-four, but in your daze, don't confuse this retailer's report with the entire market and economy.
The tables have turned, their stocks have been up, and I think they go higher still.
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
The shares are only trading at 17 times forward earnings, and might not be fully valued just yet.
Another review of the REGN charts is in order.
Buyers make or break companies with their voting or buying or betting. Somedays it's all that matters.
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.
Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'
Let's look at this impossible move on the market -- and why health care could be coming off life support.